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Abstract
We previously reported that a secreted glycoprotein YKL-40 acts as an angiogenic factor to promote breast cancer
angiogenesis. However, its functional role in normal mammary gland development is poorly understood. Here we
investigated its biophysiological activity in mammary epithelial development and mammary tissue morphogenesis. YKL-40
was expressed exclusively by ductal epithelial cells of parous and non-parous mammary tissue, but was dramatically up-
regulated at the beginning of involution. To mimic ductal development and explore activity of elevated YKL-40 during
mammary tissue regression in vivo, we grew a mammary epithelial cell line 76N MECs in a 3-D Matrigel system in the
presence of lactogenic hormones including prolactin, hydrocortisone, and insulin. Treatment of 76N MECs with recombinant
YKL-40 significantly inhibited acinar formation, luminal polarization, and secretion. YKL-40 also suppressed expression of E-
cadherin but increased MMP-9 and cell motility, the crucial mechanisms that mediate mammary tissue remodeling during
involution. In addition, engineering of 76N MECs with YKL-40 gene to express ectopic YKL-40 recapitulated the same
activities as recombinant YKL-40 in the inhibition of cell differentiation. These results suggest that YKL-40-mediated
inhibition of cell differentiation and polarization in the presence of lactogenic hormones may represent its important
function during mammary tissue involution. Identification of this biophysiological property will enhance our understanding
of its pathologic role in the later stage of breast cancer that is developed from poorly differentiated and highly invasive cells.
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Introduction
Mammary gland development during childhood does little more
than keep pace with the general growth of the body until puberty.
During puberty, the mammary gland exhibits a substantially
dynamic process through which it gives rise to highly organized
ductal branches from earliest rudimentary ducts [1,2]. The
biophysiological property of these ductal branches is characterized
by continuous proliferation, migration, and differentiation of
ductal epithelial cells and their adjacent myoepithelial cells, thus
creating epical-basal luminal buds also referred to as acini, a basic
functional unit of the mammary gland [3]. During pregnancy and
lactation, the mammary glands undergo vigorous proliferation and
differentiation into a fully branched ductal network that
orchestrates a secreted duct system capable of producing and
collecting milk protein.
It is well established that proper organization, maintenance, and
function of the mammary ducts are largely ascribed to cell-cell
adhesion and polarization of ductal epithelium and its interaction
with extracellular matrix (ECM) [4]. These epithelial cells
coordinate together to generate and maintain a polarized cellular
layer that is surrounded by myoepithelial cells and ECM, contrary
to inner acinar cells that lack attachment to ECM and rapidly
undergo apoptosis, a death program analogous to anoikis [5,6].
The ECM-rich basement membrane is able to interact with
epithelial cells through binding different integrins accumulated at
the abluminal membrane and to induce activation of FAK, PI3K,
and Bcl2; thus enhancing the epical-basal polarization and survival
of epithelial cells [7,8].
YKL-40, also known as human cartilage glycoprotein-39 or
chitinase-3-like-1, is a secreted glycoprotein originally identified
from culture medium of a human osteosarcoma cell line MG-63
[9]. Structural analyses of YKL-40 have demonstrated that YKL-
40 is highly conserved in human [10], porcine [11], cow [12],
mouse [13], rabbit [14], and goat [15]. Putative YKL-40-like
proteins were also found in Drosophila [16], bacteria [17], and
zebra fish [18]. Human YKL-40 protein contains an open reading
frame of 383 amino acids with a molecular mass of 40 kDa and it
falls into a member of chitinase or 18-glycosyl-hydrolase gene
family which can bind oligosaccharide. But it does not have
chitinase/hydrolase activity because of the substitution of an
essential glutamic acid with leucine in the chitinase-3-like catalytic
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25819domain [19,20]. YKL-40 is normally expressed by a number of
different cell types that include chondrocytes [21], synoviocytes
[22], vascular smooth muscle cells [11], macrophages [23], and
neutrophils [17]. However, its normal function in these cells is
incompletely understood. In a broad spectrum of human
inflammatory diseases, serum levels of YKL-40 are elevated,
including bacterial infections [24], rheumatoid arthritis, osteoar-
thritis [25], hepatic fibrosis [26], and bowel lesion [27]. Thus the
pathologic function of YKL-40 is implicated in the tissue
remodeling and macrophage differentiation. Recently, YKL-40
null mice have exhibited markedly diminished antigen-induced
Th2 inflammation and impaired macrophage activation and
differentiation [28].
Over the past decade, multiple independent studies have
demonstrated that high serum levels of YKL-40 are associated
with metastasis and reduced survival in a variety of human
carcinomas such as breast cancer [29], colorectal cancer [30],
ovarian cancer [31], leukemia [32], and glioblastoma [33].
Consistent with these data, our recent reports unveiled an
angiogenic signature of YKL-40 in the development of breast
cancer and brain tumor [34,35]. Although membrane receptors
specific for YKL-40 binding have not yet been identified, the
heparin-binding affinity of YKL-40 appears to be essential for its
activity, resembling the heparin-binding property of other proteins
such as extracellular matrix protein vitronectin and angiogenic
factors bFGF and VEGF [34,36,37]. Furthermore, YKL-40 was
able to induce focal adhesion kinase (FAK) and MAP kinase Erk1/
2 signaling cascades that mediate cell adhesion, spreading,
survival, and migration in vascular endothelial cells [34]. Likewise,
YKL-40 displayed the ability to trigger phophoinositide 3-kinase
(PI-3K)/AKT and MAPK signaling that regulates mitogenesis and
survival of fibroblastic cells [38].
While the expression levels of YKL-40 in normal mammary
tissue remain to be investigated, there is compelling evidence
showing that YKL-40 levels are rapidly increased in the initiation
of mammary tissue involution as compared to the levels during
pregnancy and lactation [12,15]. For example, oligonucleotide
microarray data analyzing a pregnancy-involution cycle of the
mammary tissue demonstrated that YKL-40 was ranked as one of
the top candidates in 145 up-regulated genes specific for involution
[39,40]. Consistent with these gene microarray data, YKL-40
protein levels were also detectable in milk secretion from weaning
gland of bovine and goat, but were not detectable from lactating
mammary tissue [12,15,41]. These data suggest that elevated
YKL-40 may be associated with mammary gland regression. To
establish a functional role for YKL-40 in the normal mammary
gland morphogenesis, here we tested the hypothesis that YKL-40
inhibits mammary epithelial differentiation and development
during mammary gland development.
Results
To investigate expression levels of YKL-40 during mammary
tissue development, we utilized an immunohistochemical (IHC)
approach in a series of different ages of parous and non-parous
mice, including virgin mice (3-month old), mothers at the
beginning of involution (7-month old), and parous animals (10-
month old). Hematoxylin and eosin (H & E) analysis revealed that
a few mammary ducts were scattered in fat-rich stroma from both
virgin mice and parous mice, whereas extensive secreted ducts
were observed in the tissue from early involution (Figure 1a-c). In
IHC staining, expression levels of YKL-40 were detectable
exclusively in ductal epithelial cells but not in others (e.g.
myoepithelial cells) in virgin mice. However, its levels were
noticeably evaluated in the ductal epithelial cells from weaning
tissue. After involution, the remaining ducts markedly decreased
expression of YKL-40 (Figure 1d-f), suggestive of its function
associated with ductal regression. The specificity of this anti-YKL-
40 antibody (rAY) was validated by a test that pre-incubation of
recombinant YKL-40 with rAY protected the interaction between
tissue-derived YKL-40 and rAY, whereas collagen IV failed to
resemble the inhibition of recombinant YKL-40 (Figure S1). In
addition, pre-immune serum rabbit IgG did not recognize YKL-
40 in the tissue. Staining with an epithelial marker cytokeratin-8
(CK-8) showed that ductal epithelial cells of the virgin mammary
tissue expressed CK-8, but its level was significantly reduced
during involution. In the parous mice, CK-8 was resumed to the
basal levels expressed in the virgin animals (Figure 1g-i). In
contrast, a myoepithelial marker smooth muscle alpha actin (SMa)
remained at a strong expression level in the tissue from all different
ages (Figure 1j-l), indicating that myoepithelial cells do not play a
major role in the mammary gland development. Interestingly, an
epithelial surface marker E-cadherin (E-cad) responsible for cell-
cell adhesion was significantly decreased during and after weaning
compared with the ducts from virgin mice (Figure 1m-o). These
data suggest that ductal epithelial property is lost during involution
and this physiological change may be associated with elevated
expression of YKL-40.
This in vivo data has encouraged us to test the likelihood that
increased expression of YKL-40 inhibits differentiation of
mammary epithelial cells. To explore this, we employed an in
vitro three dimensional (3-D) matrix culture system in the presence
of lactogenic hormones including prolactin (PRL), hydrocortisone
(HDC) and insulin (INS), which represents the most common in
vitro model capable of mimicking acinus-like secretion, differenti-
ation, and polarization of ductal epithelial cells in vivo [42,43]. A
normal human mammary epithelial cell line 76N MECs were
employed for the study. 76N MECs were initially established
through transduction of a gene encoding human telomerase
catalytic protein [44,45,46] and they possessed mammary stem
cell/progenitor cell properties with ability to self-renew and
differentiate into luminal epithelial and myoepithelial cells [46].
76N MECs were plated in growth factor-reduced Matrigel
supplemented with PRL, HDC, and INS over 14 days. These
cells aggregated to form an outer layer of a sphere, typically
creating a lumen in the center. This phenotype demonstrated an
apical-basal polarization of ductal epithelial cells (Figure 2a & 2b).
In contrast, lack of PRL, HDC and INS (Figure 2c) failed to
stimulate this acinar polarization. In order to validate the
differentiation and polarization capacity of 76N MECs, we tested
for both a basal cell marker integrin a6 and an apical cell marker
phosphoEzrin/Radixin/Moesin (pERM). As shown in Figure 2d
& 2e, the sphere demonstrated the polarization with strong
staining of integrin a6 on the basal side and pERM on the apical
surface. Secreted milk protein was accumulated in the lumen
(Figure 2f). In addition, cytoskeleton protein actin and E-cad were
also stained by the spheres (Figure 2g & 2h). Altogether, these
results suggest that 76N MECs retain differentiation properties of
mammary epithelial cells capable of orchestrating a secreted
luminal epithelium in vitro.
Next, we treated these cells in the 3-D system with recombinant
protein YKL-40 that was isolated and purified through a
baculoviral infection system (Figure 3A). YKL-40 was found to
inhibit the acinar structure in 14-day culture by 60% of the
controls in the absence or presence of YKL-40 small peptide (ySP)
that contains 20 amino acids of the C-terminus of YKL-40
(Figure 3B). Immunocytochemical analyses of acinus-like struc-
tures unveiled that YKL-40 dramatically restrained the alveolus
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correspondingly localize to an apical and basal side in the
presence of YKL-40, in contrast to control cells which exhibited a
larger, polarized acinus and produce milk protein in the lumen
(Figure 3C-3E). YKL-40 did not influence 76N MEC proliferation
as compared to the control cells or the cells treated with YSP in a
monolayer culture dish (Figure S2). These data suggest that YKL-
40 displays the ability to block 76N MEC secretion, differentiation,
and polarization in the presence of lactogenic hormones.
In an attempt to further determine the regulation of epithelial
secretion by YKL-40, we measured expression of a milk protein b-
casein in 76N MECs by immunoblotting and RT-PCR analysis.
Consistent with the early immunocytochemistry results, b-casein
was upregulated at both transcriptional and translational levels in
Figure 1. Expression of YKL-40 is highly increased in mammary epithelial cells at the beginning of involution when epithelial
markers diminish. Mammary tissue specimens removed from virgin mice, mothers at the initiation of involution, and parous mice were analyzed
for H & E staining (a-c), IHC of YKL-40 (d-f), CK-8 (g-i), SMa (j-l), and E-cad (m-o). Inserts in d and f represent a high magnification. Bars: 200 mm.
doi:10.1371/journal.pone.0025819.g001
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with YKL-40 abolished the induction of b-casein, confirming its
inhibitory impact on epithelial secretion. Next, to address if YKL-
40 has the ability to alter expression of E-cad and MMP-9, both of
which play an important role in the cell polarity, motility, and
extracellular matrix remodeling, the critical mechanisms that
mediate mammary gland regression during involution. YKL-40
noticeably inhibited expression of E-cad but increased MMP-9
relative to controls treated with ySP (Figure 4B). Accordingly, we
evaluated cell motility using a cell migration assay. YKL-40
increased cell migration approximately 2-fold greater than did ySP
(Figure 4C). Collectively, these data suggest that treatment of
mammary epithelial cells with YKL-40 leads to inhibition of cell
secretion, differentiation and polarization, and increases in cell
motility.
To further validate this inhibitory signature for YKL-40 in the
cells, we next determined if genetically acquired expression of
YKL-40 can resemble the functions acted by recombinant YKL-
40. Given that endogenous levels of YKL-40 in 76N MECs were
not detectable (data not shown), we engineered a full length YKL-
40 cDNA into the cells to express ectopic YKL-40. These cells
resembled the activities of the parental 76N MECs exposed to
recombinant YKL-40 in the Matrigel as studied earlier. Com-
pared to vector control cells, 76N MECs expressing YKL-40
formed smaller acinus-like spheres (Figure 5A), as a total of spheres
were reduced by 45%. Consistent with this inhibitory phenotype,
76N MECs expressing YKL-40 also demonstrated disruption of
the apical-basal polarity, when the spheres were stained with
pERM and integrin a6 (Figure 5B). The results strengthen our
hypothesis that over-expression of YKL-40 inhibits epithelial cell
differentiation and polarity.
We next sought to identify the impacts of YKL-40 on the
expression of b-casein, E-cad, MMP-9, and corresponding
invasive activity in these cells. Consistent with recombinant
YKL-40 activity, ectopic expression of YKL-40 by 76N MECs
resulted in suppression of b-casein and E-cad, but induction of
MMP-9 and its activity (Figure 6A & 6B). Accordingly, YKL-40-
expressing 76N MECs also demonstrated increased motility as cell
migration was elevated by 72% relative to the control (Figure 6C).
To further evaluate the invasive behavior acquired by the
expression of YKL-40, we plated these cells on a diluted Matrigel
that allows motile cells to spread and migrate. Following 7-day
culture, 76N MECs expressing YKL-40 migrated and invaded the
Matrigel, the phenotype contrary to the control cells that were
restricted to grow as spheres (Figure 6D). These data are highly in
line with our earlier findings employing recombinant YKL-40,
demonstrating that YKL-40 plays a key role in the inhibition of
epithelial cell differentiation and the increase of cell motility in vitro.
Furthermore, these findings supported the notion from in vivo
studies that strong induction of YKL-40 in the early involution is
associated with impaired mammary epithelial property and
subsequent mammary gland regression.
We also transplanted 76N MECs expressing YKL-40 into pre-
cleared fat-pad tissue of SCID/Beige mice to monitor whether or
not over-expression of YKL-40 has pathologic effects on normal
mammary duct development. Mammary tissue developed from
76N MECs expressing ectopic YKL-40 exhibited well-organized
epithelial ducts surrounded by fat-rich stroma, the phenotype
identical to that found in mammary tissue derived from 76N
MECs expressing an empty vector or host native cells in different
ages of mice including virgin mice, mothers at the initiation of
involution, parous and non-parous animals in H & E (data not
shown) and IHC analysis of YKL-40 (Figure S3). Although higher
levels of YKL-40 were expressed by ductal epithelial cells in
mammary tissue bearing YKL-40-expressing 76N MECs than that
in counterparts or host mammary tissue in the different ages of
mice except the involution period, none of pathogenic events was
observed. In addition, IHC analyses for ductal differentiation and
other activities in these ages did not show significant difference
between mammary tissues containing YKL-40-producing 76N
MECs, control 76N MECs, or host native cells, including: CK-8,
E-cad, SMa, estrogen receptor (ER), progesterone receptor (PR),
cell proliferation marker Ki67, and cell apoptosis staining TUNEL
(data not shown). The data suggest that YKL-40 over-expression
in normal mammary epithelial cells does not have the ability to
induce ductal pathogenesis.
Discussion
Our current study has utilized multidisciplinary approaches
including genetic engineering, 3-D Matrigel cultures, and cleared
fat-pad xenotransplantation to characterize a functional role for
YKL-40 in the normal mammary gland development. To our
knowledge, this is the first time characterizing YKL-40 in the
mammary tissue morphogenesis, which will enhance our under-
standing of biological and physiological properties of YKL-40 in
this field.
We have found that YKL-40 is expressed merely by ductal
epithelial cells in normal breast tissue at a low level throughout the
life time except involution. This evidence suggests that the low
expression of YKL-40 may be sufficient for the development of a
limited numbers of mammary ducts in non-pregnant mammary
tissue. In weaning, YKL-40 is markedly up-regulated in ductal
epithelial cells, suggesting that YKL-40 may mediate mammary
epithelial remodeling and regression. Consistent with our findings,
milk levels of YKL-40 in goat and bovine were increasingly
detectable during weaning; but were not detectable in lactation
[12,15,41]. Furthermore, in the mimicking of an in vivo
environment for ductal morphogenesis, we used a 3-D in vitro
culture system in the presence of lactogenic hormones and found
inhibitory effects of YKL-40 on epithelial cell differentiation,
secretion, and polarization, highlighting a physiological role of
YKL-40 in the inhibition of mammary duct differentiation during
Figure 2. Differentiation and polarization of 76N cells into
alveolus-like structure in 3-D Matrigel in the presence of PRL,
HDC, and INS. Normal mammary epithelial cells 76N MECs were
suspended with RPMI assay medium containing 4% Matrigel in the
presence (a,b,d, e, f, g, & h) or absence (c) of 5 mg/ml PRL, 5 mg/ml HDC
and 5 mg/ml INS for 2 weeks. Acinus-like structure was visualized under
a microscope (a). Acinar polarization was analyzed by immunofluores-
cent staining with single nuclear staining of DAPI depicting a hollow
lumen (b), and double staining using DAPI and anti-integrin a6 (d), anti-
pERM (e), anti-milk protein (f), anti-actin (g), or E-cad (h) antibody. Bars:
50 mm.
doi:10.1371/journal.pone.0025819.g002
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from baculoviral medium was applied to an affinity his-binding Ni-NTA column. The final recombinant YKL-40 was purified through a desalt PD-10
column. Samples were analyzed by immunoblotting using anti-YKL-40 polyclonal antibody (A). 76N MECs were grown in the assay medium described
in Figure 2 in the presence of 100 ng/ml ySP or YKL-40 for 2 weeks. Formation of acinus-like structure (diameter larger than 50 mm) in total colonies
was quantified from each well (B). n=5. *P,0.05 compared with control or ySP. The alveolar structure was subjected to immunofluorescent staining
using DAPI and anti-integrin a6 antibody (C), anti-pERM (D), and anti-milk protein (E) antibody. Bars: 50 mm.
doi:10.1371/journal.pone.0025819.g003
Figure 4. YKL-40 inhibits expression of b-casein and E-cadherin; but increases MMP-9 expression and cell migration. A. 76N MECs
were grown to sub-confluence and added with 100 ng/ml ySP, 100 ng/ml YKL-40 or 5 mg/ml combined PRL, HDC and INS for 2 days. Cellular protein
and RNA samples were collected to test expression of b-casein by immunoblotting and RT-PCR analysis, respectively. B. Two days following
treatment as above, cell conditioned medium and cell lysates were subjected to immunoblotting using antibodies against E-cad and MMP-9. C. Cells
were also determined for cell motility using a migration assay described in the Method and data were quantified. *P,0.05 compared with ySP
control. n=4.
doi:10.1371/journal.pone.0025819.g004
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mechanisms of how YKL-40 suppresses epithelial cell secretion
and differentiation induced by lactogenic hormones.
During mammary gland development, epithelial morphogenesis
and lateral ductal branching are controlled by a wide array of
intra- and extra-cellular cues that are initiated from a variety of
factors including: steroid hormones (e.g. estrogen and progester-
one), polypeptide hormones (e.g. PRL, placental lactogenes), and
growth factors (e.g. EGF, FGF, TGF-b, and insulin), ECM (e.g.
laminin), and their binding receptors (e.g. integrins) [1,3,47,48]. In
addition, a cell death process anoikis also plays an active role in the
polarization of luminal epithelium, the event that normally
contributes to the establishment of a hollow ductal phenotype
due to deprivation of ECM in the core of acini [5]. Aberrant
expression or dysfunction of these factors could result in disruption
of epithelial differentiation and acinar outgrowth, thus mediating
or leading to a pathogenesis associated with mammary tumori-
genesis [49,50,51]. However, over-expression of YKL-40 alone by
epithelial cells in the current study does not initiate pathogenesis
towards epithelial dysplasia, hyperplasia, or carcinogenesis. These
data suggest that YKL-40 is not tumorigenic. But, it may
collaborate with other oncogenic factors in participation of
tumorigenesis, as YKL-40-mediated inflammation is implicated
in the development of ulcerative colitis-associated neoplasia in
colorectal tissue [52,53]. It is well established that elevated YKL-
40 is associated with the malignancy of breast cancer. For
example, there is accumulating evidence indicating that elevated
serum levels of YKL-40 correlate with breast cancer progression
and decreased disease-free survival [29,54]. We recently identified
that cancer tissue expression of YKL-40 was associated with tumor
vasculature formation, demonstrating the angiogenic property for
YKL-40 during breast cancer development [34]. In context with
current findings, all the data indicate that YKL-40 plays a
pathological role in the late stages of breast cancer, rather than in
the initial phase of the cancer.
Normal mammary epithelial cells express strong E-cadherin, a
membrane protein characteristic of cell-cell tight contacts.
Dysfunction of E-cadherin is associated with loss of intercellular
adhesion, the process of which is fundamental during mammary
gland involution [55]. For example, truncated E-cadherin in
mammary epithelial cells led to cell-cell disassociation and thus loss
of ductal epithelial polarization [55]. In addition, increased
expression of MMPs in mouse mammary epithelial cells was
correlated with decreased E-cadherin, both of which mediate
disruption of cell polarity and contribute to invasiveness [56]. Our
current study found that YKL-40 inhibited E-cadherin and
induced MMP-9 expression in 76N MECs, concurrent with the
changes in cell polarity and invasiveness in 3-D Matrigel culture,
thus demonstrating an in important role played by YKL-40 during
mammary tissue remodeling and involution. We also interestingly
found that E-cadherin was decreased in parous mammary tissue.
The data suggest that its regulation may also be dependent on
other factors, not limited to YKL-40, such as hormones and their
receptors, because E-cadherin expression in breast cancer is
associated with increased levels of estrogen receptor [57,58].
There is a wealth of evidence suggesting that elevated serum
levels of YKL-40 in breast cancer patients serve as a cancer
prognostic biomarker [29,59]. However, a compelling study tested
and compared YKL-40 levels between the blood and nipple
aspirate fluid (NAF) from healthy women and patients with either
breast precancer or cancer [60]. Both pre-cancer and cancer
patients contained higher concentrations of YKL-40 in NAF than
did disease-free women. In addition, YKL-40 in NAF levels from
health subjects was 600-fold higher than serum levels of YKL-40
in these normal women or cancer patients. Thus it suggests that
NAF levels of YKL-40 may serve as a more sensitive marker than
serum levels in the assessment of breast cancer progression.
However, substantial epidemiological analyses are essential to
firmly establish the relationship between epithelial expression of
YKL-40 and pathogenesis of breast cancer from the same patients.
In summary, the data presented here identified that YKL-40
expressed exclusively by ductal epithelia has the ability to inhibit
mammary epithelial secretion and differentiation, impair epithelial
polarization, and facilitate cell motility in the presence of
lactogenic hormones, an essential mechanism that mediates
mammary tissue remodeling during involution. These findings
underscore the biophysiological activities for YKL-40 and also
support the evidence that YKL-40 is significantly elevated in the
involution. Therefore, elucidation of its inhibitory activity in
mammary epithelial cell differentiation and mammary gland
regression will help understand its pathological role in the breast
Figure 5. Ectopic expression of YKL-40 in 76N MECs results in
inhibition of cell differentiation and polarization in 3-D
Matrigel. A. 76N MECs expressing ectopic YKL-40 or vector were
employed for the study of cell differentiation in Matrigel as described in
Figure 2. The acinus-like structure was quantitatively analyzed. n=4.
*P,0.05 compared with a control group. B. Polarization of these cells in
Matrigel was co-stained with anti-pERM, anti-integrin a6 antibody, and
DAPI. Bars: 50 mm.
doi:10.1371/journal.pone.0025819.g005
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cancer cells.
Materials and Methods
Culture of 76N MECs
The cells (kindly provided by Drs. Vimla Band and Sallie Smith
Schneider) were grown in RPMI 1640 medium with glutamine
(Invitrogen) in the presence of 5 mg/ml insulin, 10 mg/ml hEGF,
5 mg/ml hydrocortisone (Sigma, MO, USA), and 10% FBS
(Invitrogen).
Generation of 76N cells stably expressing YKL-40
Full length of YKL-40 cDNA was subcloned into a retroviral
pCMV-neo-vector. 293T retroviral packaging cells were trans-
fected with YKL-40 or vector control DNA in the presence of pCL
10A1 vector using Fugene 6 (Roche, IN) as the delivery vehicle.
Forty-eight hours after transfection, the supernatant was harvested
and filtered through 0.45-mm pore size filters and the viral medium
was used to infect 76N MECs. Selection with 800 mg/ml
neomycin was started 48 hr after infection and the drug-resistant
cell populations were used for subsequent studies.
Purification of recombinant YKL-40 and polyclonal rAY
Full-length human YKL-40 cDNA with a His-tag was
subcloned into a pFastBac1 vector (Invitrogen, CA). Following
transformation and amplification in DH10Bac E. coli, bacmid
DNA containing YKL-40 was transfected into Sf9 insect cells by
using CellFECTIN reagent (Invitrogen) and baculoviral medium
was produced. A Ni-NTA column was used to purify recombinant
YKL-40 according to manufacture’s instruction (Invitrogen) and
YKL-40 pure protein was finally produced through a PD-10
desalting column (Millipore, CA). rAY was purified through an
Econo-Pac serum IgG purification kit (BioRad, Hercules, CA)
once it was generated from immunization of rabbits with a short
peptide of YKL-40 encoding C-terminus of YKL-40.
3-D Matrigel assay
76N MECs (2610
3) were suspended with 50 ml of assay medium
containing 4% growth factor-reduced Matrigel, 5 mg/ml PRL,
5 mg/ml HDC, 5 mg/ml INS and 1% heat-inactivated FBS, and
then were transferred onto 96-well plates pre-coated with a layer
of Matrigel and incubated for 10-14 days. In some conditions, the
cells were suspended with the assay medium in the presence of
100 ng/ml YKL-40 or ySP. Top gel medium was replaced with
assay medium every 4 days. To evaluate cell invasive behavior,
Matrigel concentration in the assay medium was reduced to 2%.
Migration assay
76N MECs (2610
5P) were transferred onto transwells (8 mm,
24-well plates) pre-coated with collagen IV (100 mg/ml). The
lower chamber of transwells included RPMI medium with YKL-
40 or ySP. After 4–6 hours of incubation, cells migrated to the
membrane were quantified. For migration of 76N MECs
Figure 6. Over-expression of YKL-40 in 76N MECs decreases E-cad and b-casein, but increases MMP-9 expression and cell
invasiveness. A. Cells ectopically expressing YKL-40 or vector were treated with the same condition as that used in Figure 4A. Cellular expression of
b-casein was determined by RT-PCR as described in the Method. P: PRL; H: HDC; and I: INS. B. Cells over-expressing YKL-40 or vector were analyzed for
expression of E-cad, MMP-9, and YKL-40 by immunoblotting and zymography. C. YKL-40-producing or control cells were tested for cell migration as
migrated cells were quantified. n=6. *P,0.05 compared with control cells. D. Cells over-expressing YKL-40 or vector were suspended with RPMI
assay medium containing 2% Matrigel, 5 mg/ml PRL, 5 mg/ml HDC, and 5 mg/ml INS. After 7-day incubation, cells were fixed with 2% para-
formaldehyde. Then nuclei were stained with DAPI and the cell morphology was analyzed with a single phase contrast (a, b), fluorescence (blue, c, d),
and overlapping image (e, f). Bars: 50 mm.
doi:10.1371/journal.pone.0025819.g006
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and INC) were added in the lower chamber.
Gelatin Zymography
Cell-conditioned serum-free media from 48 hr culture were
collected for a zymograph analysis as described previously [57,58].
Western Blot Analysis
Cells were collected by scrapping and extracted in a lysis buffer
(pH 7.4) containing 0.25 mM HEPES, 14.9 mM NaCl, 10 mM
NaF, 2 mM MgCl2, 0.5% NP-40, 0.1 mM PMSF, 20 mM
pepstatin A and 20 mM leupeptin. The lysates were centrifuged
at 10,000 g for 10 min at 4uC and the resulting supernatants were
collected for 10% SDS-PAGE. Proteins were transferred to a
nylon membrane (Invitrogen) and incubated with one of several
antibodies: rabbit anti-YKL-40 (rAY, 1:200), anti-b-casein (1:200,
Santa Cruz, CA), mouse anti-MMP-9 (1:500, VWR, NJ), E-cad
(1:500, Invitrogen), and actin (1:1000, Sigma, MO). Specific bands
were detected using an ECL kit (Pierce, VWR).
Immunofluorescence
Matrigel samples were fixed with 2% para-formaldehyde for
15 min and permeabilized with 0.5% Trition X-100 for 10 min at
4uC. Then the samples were incubated with primary antibodies in
PBS-base blocking solution containing 0.1% BSA, 0.2% Triton X-
100, 0.05% Tween-20, 7.7 mM NaN3, and 10% goat serum
overnight at 4uC. Primary antibodies included rabbit anti-milk
protein (1:100; Nordic Immunological Lab, Neitherlands), anti-
phospho-Ezrin/Radizin/Moesin (1:400, Cell Signaling, MA), rat
anti-integrin a6 (1:200, Millipore, MA), and mouse anti-E-cad
(1:500, Invitrogen) and anti-actin (1:1000, Sigma) antibody.
Secondary antibodies including goat anti-mouse or rabbit Alexa
Fluor 488 and Alexa Fluor 555 antibody (1:1000, Invitrogen) were
added for 1 hr at room temperature followed by nuclear staining
with DAPI (300 nM, Invitrogen).
RT-PCR
Total RNA was extracted by a Tri-reagent (Molecular Research
Inc., OH) from cell lysates. cDNA was synthesized through a
reverse transcriptional reaction in the presence of oligo(dT) and a
reverse transcriptase (Promega, WI). b-Casein cDNA was
amplified through PCR reaction in the presence of 5’ (CAAGG-
GAGACCATAGAAAGCC) and 3’ (GACACTAATGGGGT-
TATGAACTGGGGC) DNA primers which covered 600 bp of
b-casein gene. Samples (10 ml) were loaded into a 1% agrose gel to
determine gene expression levels of b-casein and GAPDH as
internal controls.
76N MEC transplantation into mammary fat-pad free
tissue in mice
All animal experiments were performed under the approval of
Institutional Animal Care and Use Committee of the University of
Massachusetts (IACUC ID 132669). Transplantation of 76N
MECs into cleared fat-pad tissue of 4-week old SCID/Beige mice
was described previously [61,62]. In brief, the 4
th nipples and their
epithelium-containing parts of the fat pad of mammary glands
were excised. The incisions were closed with stitches and seven
days later, 76N MECs (6610
6) expressing control vector or YKL-
40 were injected into the right or left cleared fat-pad tissue,
respectively. Host native fat pads and 76N MECs-injected fat pads
were removed from 3-month old virgin mice, 7-month old
mothers (twenty-one days after giving birth), 10-month old parous
mice, and 10-month old non-parous mice.
Histological analyses
Paraffin-embedded tumor tissues were cut to 6 mm thickness
and processed for immunohistochemical analysis. In brief, samples
were incubated with 3% H2O2 for 30 min to block endogenous
peroxidase activity, followed by incubation with blocking buffer
containing 10% goat serum for 1 hr. The samples then were
incubated at room temperature for 2 hr with mouse anti-Ki-67
(1:100, BD Pharmingen, San Diego, CA), E-cad (1:2000,
Invitrogen), ER (1:200, Santa Cruz), PR (1:200, Dako Inc,
Carpentaria, CA), and SMa (1:500, Dako) monoclonal antibodies,
or rabbit anti-YKL-40 (1:200) and CK8 (Abcam, Cambridge, MA)
polyclonal antibodies. Goat anti-mouse or anti-rabbit secondary
antibodies (1:100) conjugated to HRP were added for one hr.
Finally, DAB substrate (Dako Inc) was introduced for several
minutes and after washing, methyl green was used for counter-
staining. For detection of tissue apoptosis, we used the TUNEL
assay that was described in the instruction of a TACS.XL DAB in
situ apoptosis detection kit (Trevigen Inc., Gaithersburg, MD).
Supporting Information
Figure S1 Pre-incubation of rAY with recombinant YKL-
40 blocks rAY binding to tissue-derived YKL-40. Mam-
mary tissue specimens from parous mice were subjected to IHC
using rAY or pre-immune rIgG (1:200) (the top panel).
Recombinant YKL-40 or collagen IV and rAY at 10:1 molar
ratio were pre-incubated overnight at 4uC and then applied to the
tissue for IHC analysis of YKL-40 (the bottom panel). Bars:
100 mm.
(JPG)
Figure S2 YKL-40 does not have effects on proliferation
of 76N MECs. 76N MECs were treated with YKL-40 (100 ng/
ml), ySP (100 ng/ml) or PBS in the presence or absence of
prolactin (PRL, 5 mg/ml), hydrocortisone (5 mg/ml, HDC), and
insulin (5 mg/ml, INS) for 24 hr. 3H-thymide (1 mCi) was
introduced to each well for 6 hr. After extensive washes, the cells
were scraped and precipitated in 200 ml of 10% TCA and then
dissolved in 0.3 ml of 0.3 M NaOH. Radioactivity was quantified
by a liquid scintillation counter. n=5
(JPG)
Figure S3 Transplanted 76N MECs expressing ectopic
YKL-40 develop mammary tissue similar to that derived
from control MECs or host inherited cells. Mammary
tissue samples from virgin mice (a-c), mothers at the beginning of
weaning (d-f), parous (g-i), and non-parous (j-l) animals were
analyzed for IHC of YKL-40. Please note stronger expression of
YKL-40 present in epithelia from 76N MECs expressing YKL-40
(c, i, l) than those from control 76N MECs (b, h, k) or host native
cells (a, g, j). Bars: 200 mm.
(JPG)
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